ArticleNanomedicine (London, England)2025
Preparation and evaluation of oral enteric sustained-release liquid formulations of aspirin.
Article in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development of EL/PLGA nanoparticles for oral delivery of methotrexate with enhanced bioavailability and reduced toxicity.Drug delivery and translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo develop an enteric sustained-release nanoparticle formulations of aspirin for applicability to a broader population.
methodsAspirin-loaded nanoparticles were prepared using poly(lactic-co-glycolic acid) (PLGA) and the enteric polymer Eudragit L100-55 through an optimized oil-in-water emulsification solvent evaporation method. The nanoparticles were subjected to comprehensive physicochemical characterization, including particle size, zeta potential, and morphological analysis. Additionally, their stability, in vitro drug release profile, cytotoxicity, intestinal absorption, and in vivo pharmacokinetics were systematically evaluated.
resultsThe nanoparticles exhibited well-defined spherical morphology, uniform particle size, and favorable surface charge, demonstrating excellent biocompatibility. In the in vitro drug release study, AS-PLGA@NPs exhibited pronounced enterolysis effect. The morphology of the nanoparticles was confirmed by scanning electron microscopy (SEM) at different release stages. In vivo intestinal absorption and pharmacokinetic studies in rats demonstrated that AS-PLGA-EL@NPs enhanced drug absorption, prolonged drug release, and showed higher bioavailability compared to conventional enteric-coated tablets.
conclusionThe development and preparation of an oral enteric sustained-release nanoparticle delivery system for aspirin has the potential to serve a broader population, with promising applications in various therapeutic contexts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.